Literature DB >> 8682677

Vasospasm-induced myocardial infarction with sumatriptan.

L Mueller1, R M Gallagher, C A Ciervo.   

Abstract

Sumatriptan, a 5-hydroxytryptamine1, (5-HT1) receptor agonist is an effective abortive agent for migraine headaches. A common side effect in 3% to 7.9% of patients is chest pain. Although most cases of chest pain are not thought to be of cardiac origin, its mechanism is not entirely understood. Rare examples of electrocardiogram changes consistent with transient ischemia have been reported. Isolated instances of angina, arrhythmia, myocardial infarction, and death have been temporally associated with sumatriptan administration. In most cases, it is unclear whether underlying cardiovascular disease existed or contributed to this adverse event. We report the history of a 56-year-old female patient with migraine who experienced a myocardial infarction shortly after using sumatriptan, despite having had a normal cardiovascular evaluation. As she had a normal cardiac catheterization after the event, we find it probable that sumatriptan induced coronary vasospasm and myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8682677     DOI: 10.1046/j.1526-4610.1996.3605329.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  12 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries.

Authors:  Christopher M H Newman; Ian Starkey; Nigel Buller; Ricardo Seabra-Gomes; Simon Kirby; Jayasena Hettiarachchi; David Cumberland; William S Hillis
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

3.  A case of myocardial infarction with sumatriptan use.

Authors:  E Erbilen; H Ozhan; R Akdemir; M Yazici
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

Review 4.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

5.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

Review 6.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 8.  Treatment of migraine in patients with CADASIL: A systematic review and meta-analysis.

Authors:  Patrick A Glover; Eric D Goldstein; Mohammed K Badi; Tara J Brigham; Elizabeth R Lesser; Thomas G Brott; James F Meschia
Journal:  Neurol Clin Pract       Date:  2020-12

9.  The Effect of Sumatriptan in Ischemic Conditions in the Rat Heart.

Authors:  Hande Özge Altunkaynak-Çamca; Müge Tecder-Ünal; Meral Tuncer
Journal:  Turk J Pharm Sci       Date:  2018-11-20

10.  Triptans and troponin: a case report.

Authors:  Claudia R Weder; Markus Schneemann
Journal:  Orphanet J Rare Dis       Date:  2009-06-18       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.